DHODH and glioblastoma: Thus, we report here that glioblastoma cells, including TMZ-resistant cells, are specifically vulnerable to pharmacologic inhibition of the enzyme DHODH and that inhibiting de novo pyrimidine biosynthesis effectively decreases the production of rRNA in glioblastoma cells.